TGTX

TGTX

USD

TG Therapeutics Inc. Common Stock

$33.845+0.775 (2.344%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$33.070

High

$34.325

Low

$32.772

Volume

1.47M

Company Fundamentals

Market Cap

5.4B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

2.11M

Exchange

NCM

Currency

USD

52-Week Range

Low $23.6Current $33.845High $46.48

Related News

Analyst Upgrades

JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $49

JP Morgan analyst Eric Joseph maintains TG Therapeutics with a Overweight and raises the price target from $46 to $49.

View more
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $49
GlobeNewswire

TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million Raises full year 2025 global revenue target to $600 million, and raises full year BRIUMVI U.S. net revenue target

View more
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
GlobeNewswire

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of

View more
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
GlobeNewswire

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and

View more
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI